Advertisement

Topics

Silence Therapeutics accelerating into the clinic

11:56 EDT 17 Apr 2019 | Proactive Investors

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates Proactive London's Andrew Scott on the progress of its lead candidate SLN124  which is being developed to treat iron overload disorders.

It already has orphan drug designation in Europe and a phase Ib, first-in-human trial is scheduled to start in the third quarter.

Solomon also elaborates on two other exciting assets in the portfolio - one of them being SLN360 which is being developed as a potential treatment for cardiovascular disease.

Original Article: Silence Therapeutics accelerating into the clinic

NEXT ARTICLE

More From BioPortfolio on "Silence Therapeutics accelerating into the clinic"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...